JPRN-UMIN000002579招募中2 期
Clinical study evaluating efficacy of Nilotinib in CML patients - Clinical study evaluating efficacy of Nilotinib in CML patients
ara Hospital Kinki University School Of Medicine0 个研究点目标入组 20 人开始时间: 2009年10月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients suspected in accelerated phase(AP) or in blast crisis(BC). 2) Confirmed the expression of T315I mutation at genetic screening. 3) Previously treated with any other agents or therapy for CML, other than Hydroxyurea, Interferon-alfa, and Imatinib. 4) History of a invasive double cancer within 5 years before. 5) Presence of serious or uncontrolled concomitant disease. 6) Pregnancy or possibility of pregnancy positive. 7) Women with lactation status or patients who have willing of pregnancy. 8) Patients suffering mental disorder or psychotic symptom.
研究者
相似试验
进行中（未招募）
1 期
A Phase II Trial of Nilotinib in the Treatment of Patients with c-KIT Mutated Advanced Acral and Mucosal Melanoma (NICAM) - Nilotinib in the Treatment of c-KIT Mutated Melanoma (NICAM)c-KIT mutated advanced acral or mucosal melanomaMedDRA version: 10 Level: LLT Classification code 10025654 Term: Malignant melanoma of sites other than skinMedDRA version: 10 Level: LLT Classification code 10000583 Term: Acral lentiginous melanomaEUCTR2009-012945-49-GBRoyal Marsden Hosptial Foundation Trust29
尚未招募
不适用
Efficacy and safety evaluation of nilotinib as primary treatment in newly diagnosed Philadelphia chromosome positive(Ph+) chronic myeloid leukemia(CML) patientsDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0000615Seoul National University Hospital114
已完成
不适用
Clinical trial on the efficacy and safety of Nobilex 90 to fatty liverFatty liverJPRN-UMIN000034957Southern Knights' Laboratory Co., Ltd.40
进行中（未招募）
1 期
An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by RQ-PCRChronic Myelogenous Leukemia in Chronic PhaseMedDRA version: 9.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaEUCTR2009-012616-40-FRovartis Pharma Services AG192
进行中（未招募）
不适用
An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by RQ-PCRilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by RQ-PCRMedDRA version: 9.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaEUCTR2009-012616-40-GBovartis Pharma Services AG192